Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
GAITHERSBURG, Md., Dec. 28 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that it intends to develop a monoclonal...
GAITHERSBURG, Md., Dec. 20 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that it has licensed its proprietary reverse...
- Initial Focus on Monoclonal Antibody Targeting IL-5 Receptor in Phase 1 Trials with Asthma Patients - GAITHERSBURG, Md., and PRINCETON, N.J...
GAITHERSBURG, Md., Dec. 18 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced that it has completed its sale of CytoGam(R...
Households with Children in Vaccine-Program Schools Report Fewer Doctor's Office Visits, Less Absenteeism from School and Work GAITHERSBURG, Md...
ORLANDO, Fla., Dec. 9 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that results from three programs within the...
GAITHERSBURG, Md., Dec. 6 /PRNewswire-FirstCall/ -- Highlighting its proven strengths in discovering, developing and commercializing multiple...
- Appointments Strengthen Development Management Team and Augment Medical Affairs Expertise - GAITHERSBURG, Md., Dec. 5 /PRNewswire-FirstCall/...
GAITHERSBURG, Md., Dec. 1 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that the Washington Business Journal has named...
GAITHERSBURG, Md., Nov. 21 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that it will present at the Lazard Capital...
- Biotechnology Company Creates New Government Project Management Post - GAITHERSBURG, Md., Nov. 9 /PRNewswire-FirstCall/ -- MedImmune, Inc...
Company Reaches Key Milestone in Commitment to HHS and National Pandemic Preparedness GAITHERSBURG, Md., Nov. 9 /PRNewswire-FirstCall/...
GAITHERSBURG, Md., Nov. 8 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced its intent to sell CytoGam(R) (cytomegalovirus...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지